These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8518277)

  • 1. Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm.
    Hamaguchi N; Roberts H; Stafford DW
    Biochemistry; 1993 Jun; 32(25):6324-9. PubMed ID: 8518277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in hemophilia Bm occur at the Arg180-Val activation site or in the catalytic domain of factor IX.
    Bertina RM; van der Linden IK; Mannucci PM; Reinalda-Poot HH; Cupers R; Poort SR; Reitsma PH
    J Biol Chem; 1990 Jul; 265(19):10876-83. PubMed ID: 2162822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular defect in factor IX Tokyo: substitution of valine-182 by alanine at position P2' in the second cleavage site by factor XIa resulting in impaired activation.
    Maekawa H; Sugo T; Yamashita N; Kamiya K; Umeyama H; Miura N; Naka H; Nishimura T; Yoshioka A; Matsuda M
    Biochemistry; 1993 Jun; 32(24):6146-51. PubMed ID: 8512923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
    Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
    Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and characterization of human factor IX. Factor IXthr-397 and factor IXval-397.
    Hamaguchi N; Charifson PS; Pedersen LG; Brayer GD; Smith KJ; Stafford DW
    J Biol Chem; 1991 Aug; 266(23):15213-20. PubMed ID: 1907972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood clotting factor IX Niigata: substitution of alanine-390 by valine in the catalytic domain.
    Sugimoto M; Miyata T; Kawabata S; Yoshioka A; Fukui H; Takahashi H; Iwanaga S
    J Biochem; 1988 Dec; 104(6):878-80. PubMed ID: 3243764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa.
    Larson PJ; Stanfield-Oakley SA; VanDusen WJ; Kasper CK; Smith KJ; Monroe DM; High KA
    J Biol Chem; 1996 Feb; 271(7):3869-76. PubMed ID: 8632006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a factor IX variant with a glycine207 to glutamic acid mutation.
    Lin SW; Lin CN; Hamaguchi N; Smith KJ; Shen MC
    Blood; 1994 Sep; 84(6):1866-73. PubMed ID: 7915915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
    Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
    Westmark PR; Tanratana P; Sheehan JP
    J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia B caused by five different nondeletion mutations in the protease domain of factor IX.
    Ludwig M; Sabharwal AK; Brackmann HH; Olek K; Smith KJ; Birktoft JJ; Bajaj SP
    Blood; 1992 Mar; 79(5):1225-32. PubMed ID: 1346975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.
    Usharani P; Warn-Cramer BJ; Kasper CK; Bajaj SP
    J Clin Invest; 1985 Jan; 75(1):76-83. PubMed ID: 3965513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysis. Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteins.
    Spitzer SG; Warn-Cramer BJ; Kasper CK; Bajaj SP
    Biochem J; 1990 Jan; 265(1):219-25. PubMed ID: 2105717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm.
    Taylor SA; Liddell MB; Peake IR; Bloom AL; Lillicrap DP
    Br J Haematol; 1990 Jun; 75(2):217-21. PubMed ID: 2372509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X.
    Nishimura H; Takeya H; Miyata T; Suehiro K; Okamura T; Niho Y; Iwanaga S
    J Biol Chem; 1993 Nov; 268(32):24041-6. PubMed ID: 8226948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimaeric modelling.
    Miyata T; Kuze K; Matsusue T; Komooka H; Kamiya K; Umeyama H; Matsui A; Kato H; Yoshioka A
    Br J Haematol; 1994 Sep; 88(1):156-65. PubMed ID: 7803238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and function of factor IX: defects in haemophilia B.
    McGraw RA; Davis LM; Lundblad RL; Stafford DW; Roberts HR
    Clin Haematol; 1985 Jun; 14(2):359-83. PubMed ID: 3899439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding.
    Lenting PJ; Christophe OD; Maat H; Rees DJ; Mertens K
    J Biol Chem; 1996 Oct; 271(41):25332-7. PubMed ID: 8810297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein engineering of the hydrophobic domain of human factor IX.
    Hughes PE; Handford PA; Austen DE; Brownlee GG
    Protein Eng; 1994 Sep; 7(9):1121-7. PubMed ID: 7831283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of the EGF-like domain mutations Pro55Ser and Pro55Leu, which cause mild hemophilia B.
    Knobe KE; Persson KE; Sjörin E; Villoutreix BO; Stenflo J; Ljung RC
    J Thromb Haemost; 2003 Apr; 1(4):782-90. PubMed ID: 12871416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.